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H I G H L I G H T S
• Patients with carotid artery stenosis have higher levels of serum cFAS, and patients with diabetes have even higher levels of serum cFAS activity compared to
patients with no diabetes.
• Serum cFAS activity correlates with serum glucose and predominantly in LDL cholesterol fractions in patients with carotid artery stenosis.• In LDL cholesterol, cFAS immunoprecipitates with ApoB.• Patients with high serum cFAS also have high carotid plaque FAS and saturated fatty acids.• cFAS appears to originate from the liver as mice with selective knockdown of FAS in the liver tissue have the lowest serum cFAS levels.







A B S T R A C T
Background and aims: Diabetes is an independent risk factor for carotid artery stenosis (CAS). Fatty acid synthase
(FAS), an essential de novo lipogenesis enzyme, has increased activity in the setting of diabetes that leads to
altered lipid metabolism. Circulating FAS (cFAS) was recently observed in the blood of patients with hyper-
insulinemia and cancer. We thought to evaluate the origin of cFAS and its role in diabetes-associated CAS.
Methods: Patients with diabetes and no diabetes, undergoing carotid endarterectomy (CEA) for CAS, were
prospectively enrolled for collection of plaque and fasting serum. FPLC was used to purify lipoprotein fractions,
and ELISA was used to quantify cFAS content and activity. Immunoprecipitation (IP) was used to evaluate the
affinity of cFAS to LDL-ApoB.
Results: Patients with CAS had higher cFAS activity (p < 0.01), and patients with diabetes had higher cFAS
activity than patients with no diabetes (p < 0.05). cFAS activity correlated with serum glucose (p= 0.03,
r2 = 0.35), and cFAS content trended with plaque FAS content (p= 0.06, r2 = 0.69). cFAS was predominantly in
LDL cholesterol fractions of patients with CAS (p < 0.001), and IP of cFAS demonstrated pulldown of ApoB.
Similar to patients with diabetes, db/db mice had highest levels of serum cFAS (p < 0.01), and fasL−/− (tissue-
specific liver knockdown of FAS) mice had the lowest levels of cFAS (p < 0.001).
Conclusions: Serum cFAS is higher in patients with diabetes and CAS, appears to originate from the liver, and is
LDL cholesterol associated. We postulate that LDL may be serving as a carrier for cFAS that contributes to
atheroprogression in carotid arteries of patients with diabetes.
1. Introduction
Diabetes is a strong independent risk factor for cerebrovascular
disease [1,2]. At least 30% of ischemic strokes occur in a carotid artery
distribution, and are a consequence of atherosclerotic occlusive disease
leading to critical carotid artery stenosis (CAS) [3,4]. Diabetes and
serum cholesterol are known predictors for carotid atheroprogression
[3], and patients with diabetes are at particularly higher risk of de-
veloping ischemic stroke manifestations of the disease [5,6]. Although
little mechanistic information exists on the effect of diabetes on
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atheroprogression in the carotid artery [7], it is assumed that chronic
hyperglycemia, altered metabolism, and abnormal serum lipid con-
centrations can affect the incidence and severity of atherosclerosis in
patients with diabetes [8].
Fatty Acid Synthase (FAS) is an essential multi-enzyme, 273 kDa
polypeptide dimer complex that catalyzes the endogenous de novo
synthesis of saturated fatty acids (SFAs) from simple molecular pre-
cursors such as acyl-CoA and malonyl-CoA [9,10]. In the setting of
diabetes there is increased FAS gene expression and enzyme activity
[11], and a 10-fold increase in hepatic FAS-mediated lipogenesis
[9,12]. Conversely, treatment of high-fructose diet-fed db/db mice with
FAS inhibitors decreases hepatic lipid accumulation and hepatic fatty
acid oxidation [13]. Since FAS is regulated by insulin, glucagon, glu-
cose, and dietary fats, this presumed soluble cytoplasmic protein is
considered to play important roles in the pathogenesis of disorders
associated with chronic diabetes.
Recently, FAS was also identified in the blood of patients with un-
ique pathologies [14]. Circulating FAS (cFAS) is detected and elevated
in the blood stream of patients with various types of advanced cancer
[15,16], as well as in patients with age adjusted obesity-induced insulin
resistance [17]. Given these findings and the already established role of
tissue FAS in producing the metabolic building blocks for complex sa-
turated lipids, triglycerides and lipoproteins (such as VLDL and LDL)
[18], we thought to evaluate the levels of cFAS in patients with diabetes
and high-grade CAS. We also thought to evaluate the potential tissue
origin of cFAS to help explain the presence of this large homo-dimer
protein in the blood stream.
2. Materials and methods
2.1. Human study patient selection and serum preparation
From December 2016 to December 2017, an equal number of pa-
tients with diabetes and no diabetes, undergoing carotid en-
darterectomy (CEA) for high-grade (> 70%) asymptomatic or symp-
tomatic CAS, were prospectively enrolled for the collection of carotid
artery plaque tissue as well as preoperative fasting serum. Additionally,
another cohort of younger ‘healthy’ patients, with no history of arterial
occlusive disease, diabetes, or a history of current smoking was si-
multaneously recruited to obtain control fasting serum. This study was
performed using an institutional review board-approved study protocol
that conforms to the ethical guidelines of the 1975 Declaration of
Helsinki. All study patients provided written informed consent prior to
participation in the study.
Fresh human serum aliquots were collected from fasting (at least
12 h) study participants and concentrated using a 100 kDa ultrafiltra-
tion centrifuge tube (ThermoFisher Scientific, Waltham, MA), at
15,000g, for 15 min. A resultant minimum volume of 250 μL of con-
centrated serum was collected for each patient. The protein con-
centration of the concentrated human serum was assessed using a
Bradford Protein Assay (Bio-Rad Laboratories, Inc., Hercules, CA).
2.2. Fast protein liquid chromatography (FPLC)
Human serum was fractionated using FPLC (Akta FPLC; GE
Healthcare) using two tandem Superose 6 Increase 10/300 GL columns.
Phosphate buffered saline (PBS; pH 7.4) eluent buffer was first passed
through a 0.22 μm filter, at a rate of 0.2 ml/min, to ensure equilibration
of the columns. Serum sample aliquots of 500 μL were then injected into
the columns. Elutions were then carried out at a flow rate of 0.2 mL/
min 72 fractions, 0.5 mL each, were collected in separate elutant glass
tubes for subsequent cholesterol content analysis (Infinity Cholesterol
Analysis; Fisher Scientific, Waltham, MA). 10 μL aliquots from each
elutant fraction were then used to determine the discrete elution peaks
for VLDL, LDL, and HDL lipoproteins.
2.3. Animals
Adult 8-week-old wildtype (+/+) C57BL6-J mice and db/db were
commercially obtained (Jackson Laboratory, Bar Harbor, ME).
Similarly aged, hepatocyte specific and skeletal muscle specific FAS
knockdown mice (fasL−/− and fasM−/−, respectively) were generated
as previously described [19,20]. Briefly, mice were engineered with
LoxP flanked fasn gene, and crossed with mice expressing Cre Re-
combinase either via an albumin promoter or alpha-actin muscle pro-
moter. All murine housing, breeding, and experimental procedures
were performed in accordance with national and local guidelines, and
were approved by Institutional Animal Care and Use Committee.
2.4. cFAS enzyme linked immunosorbent assay (ELISA)
cFAS content in duplicate or triplicate serum and plaque samples
was performed using a commercially available cFAS ELISA assay (Aviva
Biosystems, San Diego, CA). cFAS enzymatic activity in serum and
plaque was evaluated using a malonyl CoA-dependent NADPH deple-
tion assay as previously described [21].
2.5. Co-immunoprecipitation of cFAS and apolipoprotein B (ApoB)
FPLC-derived peak LDL cholesterol fractions were collected for re-
presentative patients with diabetes. Co-immunoprecipitation of cFAS
and ApoB was performed using a Protein A Sepharose bead pulldown
assay. Refer to supplemental online material for method details.
2.6. Human and murine tissue lysis and western blotting
Fresh human plaque tissue was grossly dissected and segmented into
maximally (Max) and minimally (Min) diseased portions as previously
described and validated [22]. Segments were then immersed in cold
hypotonic non-detergent based lysis buffer (1M NaHCO3, 1M NaN3,
0.1 M PMSF, and Protease Inhibitor Cocktail Set III (Calbiochem, San
Diego, CA)) for 30 min. Specimens were homogenized with high-speed
rotational tissue homogenizer (Glas-Col, Terre Hute, IN), and cen-
trifuged at 12,000 RPM for 5 min), and supernatants were collected for
analysis.
Murine organ tissue were finely minced with a scissor and scalpel
and immersed in 1x lysis buffer (Cell Signaling Technology, Danvers,
MA)) and Protease Inhibitor Cocktail. Lysates were centrifuged, and
supernatants collected for analysis.
Human carotid plaque, and murine liver and muscle tissue homo-
genates were evaluated with Western blot. Samples were standardized
by protein concentration using a Bradford protein analysis assay (Bio-
Rad, Hercules, CA). 30 μg of protein from each sample was resolved on
a 7% SDS-TrisAcetate-polyacrylamide gel and electrotransferred onto
PVDF membranes. Membranes were then probed with an FAS antibody
and GAPDH antibody (Cell Signaling Technologies, Danavers, MA), and
Western blots were resolved with ECL kit and LI-COR imaging system.
2.7. Mass spectrometry
Modified Bligh-Dyer method [23] was performed to extract SFAs
and unsaturated fatty acids (USFAs) from 50 μL of lysates of Max dis-
eased carotid plaque segments. Refer to online supplemental methods
for additional details.
2.8. Statistical analysis
All statistical analyses were carried out using GraphPad Prism (La
Jolla, CA). Descriptive statistics are summarized as mean ± SEM, un-
less otherwise indicated. Non-parametric Mann-Whitney tests were
used for the following: to determine differences in demographic vari-
ables between patients with CAS and controls without CAS, differences
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in cFAS activity between CAS patients and controls, differences in cFAS
content in CAS patient and controls, and FAS band densitometry be-
tween minimally versus maximally diseased carotid artery segments.
Kruskal-Wallis tests were used to determine if significant differences
existed in between patients with diabetes, no diabetes, and healthy
patient controls in the following: patient demographic variables, cFAS
serum content and activity, and peak isolate FPLC fractions. Student t-
test was used to evaluate the differences in cFAS in the different the
murine lines. Spearman correlation was used to evaluate relationships
between cFAS, LDL, and serum glucose. All p≤0.05 were considered
significant.
3. Results
3.1. Patient clinical demographics
During the study period, we prospectively enrolled and evaluated
39 patients. This included 26 age and comorbidity matched patients (13
patients with type 2 diabetes and 13 patients without diabetes), who
were undergoing CEA for confirmed high-grade CAS. An additional 13
patients with no history of cardiovascular disease, diabetes, or smoking
were enrolled as controls. With the exception of history of hypertension
and the use of Metformin in patients with diabetes, there were no other
significant differences between the demographics of the patient with or
without diabetes enrolled in this study (Table 1). In comparison, control
patients were significantly younger, did not have any cardiovascular co-
morbidities, and were mostly female (p < 0.05).
3.2. cFAS content and activity is elevated in patients with diabetes and high-
grade CAS
Compared to patients no CAS, patients with CAS had significantly
elevated serum cFAS content (1.1 ± 0.2 versus 5.0 ± 0.9 respectively;
p < 0.001; Fig. 1A). Additionally, patients with CAS had higher cFAS
enzyme activity compared to controls (5.6 ± 0.5 vs. 2.9 ± 0.7 pmoles
of NADPH consumed, respectively; p < 0.01; Fig. 1B). Patients with
diabetes had significantly higher cFAS enzyme activity compared to
patients with no diabetes (p < 0.05) and control patients (p < 0.01;
Fig. 1C). No differences in serum cFAS activity were observed between
patients with symptomatic versus asymptomatic CAS, or a history of
coronary artery disease (CAD; Supplemental Figs. 1A and B). Similarly,
no differences in serum cFAS activity were observed relative to gender,
age, or BMI (Supplemental Figs. 1C–E).
3.3. cFAS correlates with serum glucose and LDL cholesterol
Serum cholesterol and glucose correlate with the severity of ather-
osclerotic disease in patients with diabetes, and LDL is a known in-
dependent risk factor for CAS [24] and stroke [25]. We therefore
evaluated the relationship between serum cFAS, glucose, and LDL.
Patients with diabetes had significantly elevated fasting serum
glucose compared to patients without diabetes (p < 0.05; Fig. 2A). We
observed that cFAS activity had a significant positive correlation with
serum glucose (Spearman R2 = 0.35, p= 0.03; Fig. 2B). cFAS content
did not correlate with serum glucose (Fig. 2C). There was no significant
difference in fasting serum LDL cholesterol between patients with and
without diabetes and controls (Fig. 2D), and there was no meaningful
correlation between cFAS content/activity and serum LDL cholesterol
(Fig. 2E and F). Similarly, no differences in total cholesterol and serum
triglycerides were observed between the study groups, and no corre-
lations were observed between these variables and cFAS content/ac-
tivity (Supplemental Fig. 2).
3.4. FAS content is elevated in maximally diseased carotid plaque segments
Carotid plaque from patients enrolled in the study was collected and
analyzed for FAS content in the maximally (Max) and minimally (Min)
diseased plaque portions (Fig. 2G). No difference in fasn RNA transcript
was observed in Max and Min diseased CEA plaque segments of patients
with or without diabetes (Fig. 2H). However, we observed that Max
diseased CEA plaque segments had 2.5 times higher FAS protein content
(p < 0.05; Fig. 2I and J). Patients with diabetes also demonstrated a
39% higher FAS content in Max diseased carotid segments compared to
patients with no diabetes (p > 0.05; Fig. 2K). The relative content of
FAS in CEA plaque and serum cFAS activity in the same patients de-
monstrated a moderate but non-significant correlation (Spearman
r2 = 0.69; p= 0.06; Fig. 2L). There was also a higher content of SFAs in
Max diseased CEA plaque segments of patients with diabetes
(p < 0.001; Fig. 2M).
3.5. cFAS is associated with LDL cholesterol and ApoB
Using FPLC techniques VLDL, LDL, and HDL cholesterol fractions
were isolated from fasting serum of control patients, and patients with
diabetes and no diabetes (Fig. 3A). We observed that LDL cholesterol
was the dominant lipoprotein in the serum of patients in all study
groups (Fig. 3B). While there was no significant differences observed in
VLDL, LDL, or HDL isolate fraction levels between the study patient
groups (Fig. 3B), total FPLC-derived cholesterol content was observed
to be lowest in patients with diabetes, and significantly less than control
patients (p < 0.05; Fig. 3C). This is likely because all patients with CAS
were receiving moderate to high doses of Atorvastatin, Rosuvastatin, or
Simvastatin (Table 1).
cFAS was nearly exclusively found in LDL cholesterol fractions of
patients with and without diabetes (p < 0.001; Fig. 3D). Approxi-
mately 5% of total cFAS activity was observed in the VLDL fractions
(Fig. 3D). cFAS activity in LDL cholesterol fractions from patients with
diabetes was significantly higher compared to patients with no diabetes
(p < 0.05; Fig. 3E), and confirms that cFAS in cholesterol fractions was
Table 1
Demographic variables of study patients.
Demographics Diabetes and
CEA (n = 13)
No diabetes and




Diabetes 13 0 0
Gender (F) 4 2 10
Age
< 50 0 0 12
50-60 2 2 1
61-70 5 4 0
71-80 4 7 0
> 80 2 0 0
BMI 4 3 4
Current smoker 0 0 1
Symptomatic CAS 6 5 0
Asymptomatic CAS 7 8 0
History of prior stroke 4 3 0
Peripheral artery disease 1 3 0
Coronary artery disease 2 5 0
Hypertension* 13 8 0
Hyperlipidemia 11 13 0
Renal insufficiency 0 0 0
Heart arrhythmia 3 1 0
Valvular heart disease 4 3 0
Alcohol abuse 0 0 0
Medications
ACE inhibitor 9 5 0
Beta blocker 7 7 0
Aspirin 9 12 0
Other antiplatelet 4 5 0
Statin 13 13 0
Insulin 0 0 0
Metformin* 9 0 0
*p < 0.05, Mann-Whitney U test.
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still biochemically active.
To determine whether cFAS interacts with serum VLDL and LDL we
evaluated whether it co-immunoprecipitates with ApoB the pre-
dominant protein in these lipoproteins [26,27]. Immunoprecipitation of
ApoB from LDL cholesterol fractions demonstrated positive pulldown of
cFAS (Fig. 3F and E). Conversely, immunoprecipitation of cFAS from
LDL cholesterol fractions demonstrated positive pulldown of ApoB
(Fig. 3H).
3.6. cFAS is elevated in mice with diabetes and is produced by the liver
Adult db/db mice (which have an advanced end-stage diabetes
phenotype) had elevated tissue FAS in the liver and anterior tibalis
skeletal muscle (p < 0.05; Fig. 4A–D). Similar to patients with diabetes
in our human study, db/db mice also demonstrated elevated serum cFAS
(p < 0.01; Fig. 4E and F). Compared to +/+ mice, mice with tissue-
specific FAS knockdown in hepatocytes (fasL−/−) had significantly
Fig. 1. Serum cFAS is elevated in patients with CAS
and diabetes.
(A) cFAS content (ng/μL) in the fasting serum of
patients diagnosed with high-grade CAS and sched-
uled for CEA (n = 26) was compared to fasting
serum of patients who do not have CAS or other
major cardiovascular co-morbidities (n = 13).
Patients with high-grade CAS demonstrated sig-
nificantly higher cFAS content in their fasting serum
compared to control patients. Control patients con-
sistently demonstrated low serum cFAS content.
***p < 0.001, Mann-Whitney. Error bars represent
the SEM. (B) cFAS enzyme activity (arbitrary units, AU) was also evaluated between patients with high-grade CAS (n = 26) and control patients (n = 13). Patients
with high-grade CAS demonstrated significantly higher cFAS enzyme activity compared to control patients **p < 0.01, Mann-Whitney. Error bars represent the
SEM. (C) Patients with diabetes and CAS (n = 13) had the highest levels of cFAS enzyme activity compared to patients with no diabetes and CAS (n = 13), and
control patients (n = 13). *p < 0.05, **p < 0.01, Kruskal-Wallis. Error bars represent the SEM.
Fig. 2. Serum cFAS correlates with serum
glucose and carotid plaque FAS and satu-
rated fatty acid content.
(A) Serum cFAS activity and content were
evaluated in patients with diabetes and CAS
(n = 13), patients with no diabetes and CAS
(n = 13), and controls with no diabetes and
no CAS (n = 13). Patients with diabetes and
CAS have significantly higher serum glucose
compared to patients with no diabetes and
CAS. *p < 0.05, Kruskal-Wallis. Error bars
represent the SEM. cFAS activity (B) but not
content (C) has a significant correlation
with serum glucose (patient with diabetes
and CAS, triangle; patient with no diabetes
and CAS, square; patient control with no
CAS, circle). r2, Spearman correlation. (D)
No significant difference was observed in
serum LDL between patients with and
without diabetes, and control patients. (E
and F) No correlation was observed be-
tween cFAS activity/content and LDL. (G)
Open exposure of the right carotid artery
bifurcation with the head towards the left
(cranial) and the feet towards the right
(caudal). Visible within the clamped carotid
bifurcation is irregular ulcerated plaque.
Extracted CEA plaque demonstrates a
minimally (Min) diseased portion at the
distal edge, and a maximally (Max) diseased
portion at the carotid bifurcation region.
(H) fasn RNA transcript between Max and
Min diseased CEA portions was evaluated
using RT-PCR. No differences were ob-
served in fasn and between patients with
and without diabetes. (I) FAS protein con-
tent in CEA plaque homogenates were
evaluated by Western blot analysis. (J)
Higher levels of FAS were observed in Max diseased plaque compared to Min diseased plaque (n = 6 patients). *p < 0.05, Mann-Whitney U test. Error bars represent
the SEM. (K) FAS protein content in CEA plaque homogenates was evaluated using ELISA. Compared to patients with no diabetes, there was a 39% increase in FAS in
the Max and Min CEA plaques of patients with diabetes. Error bars represent the SEM. (L) FAS protein content in CEA plaque demonstrated a moderate correlation
with serum cFAS activity, but this difference was not statistically significant. r2, Spearman correlation; p = 0.06. (M) The ratio of the relative content of total
saturated fatty acid (SFA) to total unsaturated fatty acid (USFA) was significantly higher in the Max CEA plaques of patients with diabetes. **p < 0.001, Kruskal-
Wallis. Error bars represent the SEM.
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reduced serum cFAS (p < 0.01; Fig. 4E and F), suggesting that the liver
produces the majority of cFAS. On the other hand, tissue-specific FAS
knockdown in skeletal muscle (fasM−/−) had no reduction in serum
cFAS (Fig. 4E and F), suggesting that skeletal muscle is not a major
source of cFAS.
4. Discussion
Diabetes is a strong, independent risk factor for stroke and cere-
brovascular disease-associated mortality [2,5,6]. The relative risk con-
ferred by diabetes is over and above the effect of mean arterial blood
Fig. 3. Serum cFAS content and activity is elevated
in serum LDL cholesterol isolates and co-im-
munoprecipitates with ApoB.
(A) Fasting serum from patients with diabetes and
CAS (n = 13), no diabetes and CAS (n = 13), and
control patients (n = 13). Serum was added to an
FPLC column and cholesterol isolate concentrations
were evaluated to determine VLDL, LDL, and HDL
concentrations. (B) Although control patients de-
monstrated a mild non-significant increase in serum
LDL, no differences in VLDL and HDL were observed
between the study groups. (C) Area under the curve
(AUC) analysis demonstrated an overall increase in
cholesterol isolates in control patients relative to
patients with and without diabetes and CAS.
*p < 0.05, Kruskal-Wallis. Error bars represent the
SEM. (D) cFAS content in peak VLDL, LDL, and HDL
isolates was evaluated with ELISA from patients with
diabetes (n = 8) and patients with no diabetes
(n = 7). The LDL peak isolate demonstrated the
highest levels of cFAS. ***p < 0.001, Kruskal-
Wallis. Error bars represent the SEM. (E) cFAS ac-
tivity in LDL peak isolates from patients with dia-
betes (n = 5) and patients with no diabetes (n = 5)
was evaluated by FAS activity assay. This demon-
strated significantly higher FAS activity levels (arbi-
trary units; AU) in peak LDL isolates of patients with
diabetes. *p < 0.05, Mann-Whitney. Error bars represent the SEM. (F and G) Serum LDL fractions from a patient with diabetes was collected and ApoB im-
munoprecipitated. Wash, eluent, and immunoprecipitation (IP) fractions were collected. Subsequent Western blots were performed for ApoB (F) and FAS (G). An
FPLC purified LDL fraction (30 μg of protein) was used as positive control for the ApoB blot, and a murine liver homogenate (10 μg of protein) was used as positive
control for the FAS blot. (H) Similarly, serum LDL fractions from a patient with diabetes (1) and a patient with no diabetes (2) were collected and FAS was
immunoprecipitated. The procedure wash, eluent, and IP fractions were collected and Western blots performed for ApoB (top blot), and FAS (bottom blot). Whole
serum (30 μg of protein), murine liver homogenate (2.5 μg of protein) was used as positive control for ApoB and FAS blots, respectively.
Fig. 4. Differential expression of FAS and
cFAS in murine tissue-specific liver and
skeletal muscle FAS knockdowns.
(A) FAS protein content from liver homo-
genates of +/+, db/db, fasL−/−, and
fasM−/− mice were evaluated using
Western blotting. (A and B) fasL−/− mice
demonstrated significantly less FAS in the
liver, while db/db mice demonstrated sig-
nificantly higher FAS in the liver.
*p < 0.05. Error bars represent the SEM.
(C) FAS protein content from anterior ti-
bialis muscle homogenates from the same
mouse groups was also evaluated using
Western blotting. (C and D) fasM−/− mice
showed significantly less FAS in the muscle
tissue, and db/db mice also showed sig-
nificantly higher FAS in the muscle.
*p < 0.05. Error bars represent the SEM.
(E) Whole serum was collected from all
mouse groups, and cFAS was then evaluated
using Western blot. fasL−/− mice had sig-
nificantly less cFAS compared to +/+ and
fasM−/−. db/db mice had significantly
higher cFAS compared to all other mouse
groups. **p < 0.01. Error bars represent
the SEM. GAPDH blot was used as loading
control for all Western blots.
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pressure, cigarette smoking, and total serum cholesterol [1]. Here we
demonstrate that cFAS correlates with the presence of high-grade CAS
in patients with diabetes. We also demonstrate that cFAS is present and
biochemically active in non-HDL serum fractions, and likely originates
from the liver. Carotid plaque isolated from patients with and without
diabetes demonstrates variable FAS content, with more FAS and SFAs in
the Max diseased carotid segments and in plaques isolated from patients
with diabetes. These findings highlight cFAS as a potential novel and
important contributor to CAS in patients with diabetes.
The patho-metabolic pathway for the markedly elevated risk of CAS
in patients with diabetes is yet to be determined. Recent studies have
focused on the role of wide-ranging endogenous metabolic pathways
such as glycosylation of the carotid arterial wall [28], micro-
albuminuria [29], hypertriglyceridemia [30], and low serum HDL le-
vels [31,32]. Serum LDL is a known contributor to diabetes-related
metabolic derangements [33], and is also an independent risk factor for
the incidence of cerebrovascular disease [34]. Patients with diabetes
and elevated LDL are more likely to have symptomatic carotid artery
stenosis, transient ischemic attacks, and resultant strokes [35]. How-
ever, several recent studies have proposed that LDL content alone does
not fully explain the higher risk of stroke in patients with diabetes who
also receive statin and other cholesterol lower therapy [36,37]. A recent
meta-analysis of over 18,000 patients with diabetes demonstrated de-
creased stroke events in patients receiving cholesterol-lower therapy.
However, among patients receiving cholesterol-lower therapy, patients
with diabetes still had a 39% relative increase in stroke events com-
pared to patients with no diabetes [36]. Recent reports also argue that
ApoB, the predominant protein in non-HDL cholesterol, is a more im-
portant predictor of cardiovascular disease [38,39]. Thus, it is currently
unclear whether specific serum molecular factors can interact with
ApoB and/or non-HDL cholesterol to ultimately influence atheropro-
gression in the peripheral arterial system.
We observed a significant positive correlation between cFAS activity
and serum glucose. This finding is consistent with our observation that
cFAS activity is elevated in the serum and LDL cholesterol fractions of
patients with diabetes, and may be a reflection of the extent of insulin
resistance in our study patients [17]. Previously, hyperinsulinemia as a
result of insulin resistance in the setting of diabetes was observed to be
an important FAS effector. Not only does insulin increase the rate of
fasn gene transcription [12,40], but it also increases FAS enzyme ac-
tivity as observed in our study in patients with diabetes. Insulin-induced
FAS overexpression also leads to downstream transcription factor ac-
tivation [40], altered cellular metabolism, and modified cell membrane
composition in the liver, skeletal muscle, and adipose tissue [41]. Re-
cently one study demonstrated that deletion of FAS in macrophages
prevented diet-induced insulin resistance and membrane retention of
cholesterol [42]. These findings highlight that the response to insulin
and metabolic stress in the setting of diabetes can affect FAS activity
and cholesterol homeostasis.
Previous work demonstrates that FAS is glycosylated, and this is
essential for its allosteric confirmations necessary for its catalytic do-
mains [43]. This could help explain why unlike cFAS activity, cFAS
content did not correlate with serum glucose. Similarly, although we
observed that cFAS activity was higher in the serum of patients with
diabetes compared to patients without diabetes, we did not observe a
similar difference in the cFAS content between these groups (data not
shown). Our findings suggest that although patients with CAS have an
overall higher level of serum cFAS (Fig. 1A), patients with diabetes who
are more prone to have elevated serum glucose levels are more likely to
have active serum cFAS, which can lead to downstream consequences.
The role of FAS in atheroprogression has never been previously
explored. In this study, we provide the first evidence that implicates
FAS in both the plaque tissue and serum of patients with high-grade
CAS. The incremental difference in cFAS activity in patients with dia-
betes and CAS suggests that cFAS is a marker of advanced athero-
sclerotic disease in patients who are typically at higher risk for cere-
brovascular complications. Additionally, differential FAS content in
variably diseased carotid plaque suggests that FAS localizes to areas of
higher carotid disease burden. Presumably, local factors within the
arterial wall can influence FAS expression and content within the
plaque. Although we observed clear differences in the content of FAS
and SFAs in Max diseased plaque portions and in patients with diabetes
(Fig. 2J–M), we observed no difference in carotid plaque fasn expres-
sion in patients with and without diabetes (Fig. 2H). One potential
explanation for this is that VLDL lipoproteins derived from the liver that
are subsequently converted to LDL in the intravascular space, may serve
as carriers for cFAS cargo that is ultimately delivered to the peripheral
arterial wall (Fig. 5). Increased active cFAS in the vessel wall can in turn
lead to further accumulation of SFAs, that can lead to plaque in-
flammation, lesion progression and instability [44].
Our study establishes a novel link between cFAS and LDL, and de-
monstrates a unique biochemical interaction between cFAS and ApoB.
Previous studies provided a link between FAS and lipoproteins pro-
duced by the liver [43]. For example, in human subjects who consumed
diets high in carbohydrates (10% of calories as fat and 75% as carbo-
hydrates) hepatic FAS was found to be responsible for the synthesis of
the majority of circulating VLDL triglycerides [45]. Interestingly, the
lipoprotein contributions from hepatic FAS were not as high in patients
who consumed high fat and carbohydrate Western diets [18]. This
unexpected finding may have underestimated the role of FAS, since
lipoprotein contributions from extra-hepatic FAS and cFAS was not
evaluated. The content, activity, and contributions of cFAS in diet-in-
fluenced lipoprotein production are currently unknown. Similarly, the
contribution of cFAS to lipoprotein content in patients with diabetes
with variable degrees of metabolic stress and peripheral atheropro-
gression is yet to be explored and is certainly a ripe area for future
investigation.
We observed a marked decreased in serum cFAS in fasL−/− mice.
This highlights that the liver produces the bulk of cFAS, while no
change in the level of cFAS in fasM−/− mice demonstrates that skeletal
muscle is not a major source of cFAS. These findings are consistent with
prior findings that in the fed state hepatic FAS can synthesize lipids that
are either stored as lipid droplets and/or secreted in VLDL [43]. In both
human subjects with non-alcoholic fatty liver disease and ob/ob mice,
increased hepatic FAS activity is thought to be an important contributor
Fig. 5. cFAS originates from the liver and may be transported by LDL to the
peripheral vasculature to influence plaque formation.
cFAS produced by the liver is extruded into the blood stream in semi-soluble
form conjugated to ApoB in non-HDL cholesterol particles such as VLDL and
LDL. Intravascular LDL particles traverse the endothelium along with their cFAS
cargo, which is then delivered to the sub-endothelium. Accumulation of cFAS in
the sub-endothelium is thought to contribute to SFA plaque content and per-
ipheral arterial atheroprogression.
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to the development of fatty liver [27]. Additionally, genetic alteration
of FAS expression in the liver imposes significant metabolic con-
sequences to the host [23]. Therefore, the contributions of the liver to
cFAS are logical and would also be consistent with the proposed model
of cFAS trafficking from the liver to the peripheral vasculature via li-
poprotein particles also synthesized by the liver.
We acknowledge that our study has some limitations. First, the
limited number of patients evaluated here can lead to sampling error
and not fully account for the range of other pathologies that affect
patients with CAS. Future studies will aim to enroll larger patient
groups for further validation and confirmation across various patient
demographics. Second, with the limited number of patients in each
group we were not able to fully match for age and gender demographics
particularly in the control group. It is possible that age and gender
could have confounded our data in the control patient group, although
we observed that age and gender in CAS patients did not have a sig-
nificant effect on cFAS (Supplemental Fig. 1C&D). Third, FPLC techni-
ques do not differentiate between LDL and LDL-like particles (such as
Lipoprotein(a)). It is possible that cFAS differentially associates with
such particles, and further fractionation of FPLC-derived LDL isolates
may help determine this. Furthermore, we acknowledge that the role of
cFAS in atheroprogression cannot be proven except with a prospective
modulation of the enzyme. Immediate next steps to evaluate this are
focusing on the rate of atheroprogression in fasL−/− and db/db mice
treated with selective cFAS inhibitors. These studies are anticipated to
determine whether cFAS indeed plays an essential role in atheropro-
gression and plaque instability.
In conclusion, we are the first to report that cFAS is present in high
levels in patients with CAS, and enzyme activity is particularly higher in
patients with diabetes. We also observed that cFAS correlates with
serum glucose, interacts with LDL cholesterol particles, and correlates
with carotid plaque FAS. We postulate that VLDL and LDL are carriers
of cFAS cargo to the peripheral carotid tissue of patients with diabetes
leading to increased risk of atheroprogression.
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